Hui Li

Hui Li

Auto-generated profile, based on publicly available information

Hui Li

State Key Laboratory of National Security Specially Needed Medicines Beijing China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2026 in Advanced Science
Verified
Journal Article
Open access
HLHui Li
Hui Li
BZBohan Zhang
Bohan Zhang
CSChao Shang
Chao Shang
YLYi Li
Yi Li
TZTe Zhao
Te Zhao
ZLZhiping Li
Zhiping Li
The persistent evolution of SARS‐CoV‐2 and the concomitant risk of life‐threatening hyperinflammation, such as cytokine storm syndrome, underscore the urgent need for therapeutic strategies that simultaneously target viral replication and dysregulated host immunity. Herein, we describe a dual‐membrane biomimetic nanoplatform, designated [A&T]MLN, comprising siRNA‐loaded lipid nanoparticles with a hybrid membrane derived from ACE2‐overexpressing HEK293T cells and THP‐1 macrophages. This design integrates a high‐density viral decoy based on ACE2 with the inherent immunomodulatory capacity of macrophage membranes. [A&T]MLN demonstrates broad‐spectrum and potent neutralization of diverse SARS‐CoV‐2 variants by competitively blocking viral entry, while actively scavenging key inflammatory cytokines (including IL‐6, IL‐1β, and TNF‐α) via membrane‐displayed receptors. In a murine model of acute lung injury that recapitulates COVID‐19 immunopathology, [A&T]MLN treatment significantly attenuated pulmonary inflammation and tissue damage. Additionally, the platform enabled efficient cytosolic delivery of siRNA, establishing a third modality for intracellular suppression of viral gene expression. Collectively, [A&T]MLN represents a complementary triple‐modal therapy that simultaneously addresses viral entry, intracellular replication, and hyperinflammation (the core interconnected pathologies of severe COVID‐19), offering a versatile and adaptive strategy against evolving SARS‐CoV‐2 variants and related inflammatory syndromes.